Group Gp Lp Column III Buys 315,457 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 315,457 shares of the firm’s stock in a transaction dated Thursday, November 13th. The shares were bought at an average price of $12.65 per share, for a total transaction of $3,990,531.05. Following the completion of the transaction, the insider owned 962,718 shares of the company’s stock, valued at approximately $12,178,382.70. This trade represents a 48.74% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Surrozen Trading Up 1.2%

Shares of Surrozen stock opened at $12.95 on Wednesday. The company’s 50-day moving average price is $12.86 and its 200-day moving average price is $10.62. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $18.17. The company has a market cap of $110.98 million, a price-to-earnings ratio of -0.58 and a beta of 0.64.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The firm had revenue of $0.98 million for the quarter. On average, sell-side analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Investors Weigh In On Surrozen

Large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its stake in shares of Surrozen by 37.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock valued at $1,034,000 after buying an additional 24,000 shares during the period. Driehaus Capital Management LLC bought a new stake in Surrozen in the first quarter valued at $2,390,000. Stonepine Capital Management LLC boosted its holdings in Surrozen by 108.3% in the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company’s stock valued at $3,332,000 after acquiring an additional 148,582 shares in the last quarter. Vivo Capital LLC purchased a new position in Surrozen during the 1st quarter valued at $3,032,000. Finally, RA Capital Management L.P. raised its holdings in Surrozen by 140.3% in the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock worth $7,919,000 after purchasing an additional 396,550 shares in the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SRZN shares. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.